Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s10549-018-5005-6.

Title:
Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis | Breast Cancer Research and Treatment
Description:
Background Metaplastic breast cancer (MpBC) is a rare histological subtype of breast cancer recognized as a unique pathologic entity in 2000. However, the pathogenesis, optimal therapy, and prognosis of MpBC and the potential effect of systemic treatments on different subtypes of MpBC are not well defined. Methods A retrospective population-based study was performed to identify breast cancer patients with MpBC and other triple-negative breast cancers (TNBC) between 2010 and 2014 using the surveillance, Epidemiology, and End Results (SEER) database. Chi-square test was used to analyze characteristics between subgroups. Kaplan–Meier analysis and Multivariate Cox regressions were used to evaluate overall survival (OS) of MpBC, TNBC, and MpBC subgroups. Competing risk analysis and multivariate regression model of competing risk were used to assess breast cancer-specific survival (BCSS) of MpBC and TNBC Results We identified a study cohort of 22,433 patients (1112 MpBC and 21,321 TNBC). MpBC correlated with older population, larger tumor size and less lymph node involvement, and TNBC phenotype. Patients with MpBC especially with triple-negative subtype (TN-MpBC) had worse survival than the overall TNBC population. However, the prognosis of MpBC without triple-negative subtype (non-TN MpBC) was not different from that of TNBC. In Kaplan–Meier analysis, chemotherapy was not associated with significant difference in OS of TN-MpBC. In non-TN MpBC group, the 3-year OS was 79.8% for patients receiving chemotherapy and 70.5% in patients without chemotherapy, and chemotherapy was associated (P = 0.033) with improved OS. Within the MpBC patients, radiotherapy was significantly (HR 1.544; 95% CI 1.148–2.078; P = 0.004) associated with improved OS and (HR 1.474; 95% CI 1.067–2.040; P = 0.019) BCSS. Conclusions Patients with TN-MpBC had worse prognosis than TNBC and chemotherapy was not associated with improved survival. In contrast, non-TN MpBC may derive survival benefit from chemotherapy and radiotherapy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

breast, cancer, article, pubmed, google, scholar, metaplastic, mpbc, cas, prognosis, patients, survival, analysis, carcinoma, lee, triplenegative, tnbc, central, research, subtype, chemotherapy, httpsdoiorgs, yeung, subtypes, wang, study, surveillance, results, access, park, res, university, privacy, cookies, content, data, clinical, xuexin, liu, competing, worse, kim, anderson, usa, supported, center, department, journal, publish, search,

Topics {✒️}

month download article/chapter sai-ching jim yeung triple-negative breast cancers triple-negative breast cancer claudin-low breast cancers claudin-low intrinsic subtype triple-negative subtype chongjian wang metaplastic breast cancer program research data retrospective population-based study breast cancer recognized surveillance research program natl cancer inst full article pdf perlmutter cancer center metaplastic breast carcinoma derive survival benefit privacy choices/manage cookies national comprehensive cancer lymph node involvement national cancer institute rare histological subtype ductal breast carcinoma bassett rl jr metaplastic sarcomatoid carcinoma unusual disease population-based analysis breast cancer jung sy bmc cancer 15 check access instant access patients receiving chemotherapy unique pathologic entity chi-square test multivariate cox regressions larger tumor size infiltrating ductal carcinoma villarreal-colin sp herrera-montalvo la cantu de leon poor immunohistochemistry factors bristol-myers squibb 2nd affiliated hospital ethics declarations conflict bristol-myer squibb kaplan–meier analysis cancer res 69 conditions privacy policy

Questions {❓}

  • Tseng WH, Martinez SR (2011) Metaplastic breast cancer: to radiate or not to radiate?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis
         description:Metaplastic breast cancer (MpBC) is a rare histological subtype of breast cancer recognized as a unique pathologic entity in 2000. However, the pathogenesis, optimal therapy, and prognosis of MpBC and the potential effect of systemic treatments on different subtypes of MpBC are not well defined. A retrospective population-based study was performed to identify breast cancer patients with MpBC and other triple-negative breast cancers (TNBC) between 2010 and 2014 using the surveillance, Epidemiology, and End Results (SEER) database. Chi-square test was used to analyze characteristics between subgroups. Kaplan–Meier analysis and Multivariate Cox regressions were used to evaluate overall survival (OS) of MpBC, TNBC, and MpBC subgroups. Competing risk analysis and multivariate regression model of competing risk were used to assess breast cancer-specific survival (BCSS) of MpBC and TNBC We identified a study cohort of 22,433 patients (1112 MpBC and 21,321 TNBC). MpBC correlated with older population, larger tumor size and less lymph node involvement, and TNBC phenotype. Patients with MpBC especially with triple-negative subtype (TN-MpBC) had worse survival than the overall TNBC population. However, the prognosis of MpBC without triple-negative subtype (non-TN MpBC) was not different from that of TNBC. In Kaplan–Meier analysis, chemotherapy was not associated with significant difference in OS of TN-MpBC. In non-TN MpBC group, the 3-year OS was 79.8% for patients receiving chemotherapy and 70.5% in patients without chemotherapy, and chemotherapy was associated (P = 0.033) with improved OS. Within the MpBC patients, radiotherapy was significantly (HR 1.544; 95% CI 1.148–2.078; P = 0.004) associated with improved OS and (HR 1.474; 95% CI 1.067–2.040; P = 0.019) BCSS. Patients with TN-MpBC had worse prognosis than TNBC and chemotherapy was not associated with improved survival. In contrast, non-TN MpBC may derive survival benefit from chemotherapy and radiotherapy.
         datePublished:2018-10-19T00:00:00Z
         dateModified:2018-10-19T00:00:00Z
         pageStart:329
         pageEnd:341
         sameAs:https://doi.org/10.1007/s10549-018-5005-6
         keywords:
            Metaplastic breast cancer
            Breast cancer subtype
            Chemotherapy
            Radiotherapy
            Prognosis
            Cancer-specific survival
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-5005-6/MediaObjects/10549_2018_5005_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-5005-6/MediaObjects/10549_2018_5005_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-5005-6/MediaObjects/10549_2018_5005_Fig3_HTML.png
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:173
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Xuexin He
               url:http://orcid.org/0000-0002-4178-1339
               affiliation:
                     name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
                     address:
                        name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
                        type:PostalAddress
                     type:Organization
                     name:The University of Texas MD Anderson Cancer Center
                     address:
                        name:Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Jiali Ji
               affiliation:
                     name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
                     address:
                        name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rongrong Dong
               affiliation:
                     name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
                     address:
                        name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hong Liu
               affiliation:
                     name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
                     address:
                        name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xiaolan Dai
               affiliation:
                     name:Shantou University
                     address:
                        name:Department of Pharmacology, Shantou University, Shantou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chongjian Wang
               affiliation:
                     name:Zhengzhou University
                     address:
                        name:Department of Biostatistics, Zhengzhou University, Zhengzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Francisco J. Esteva
               affiliation:
                     name:NYU Langone Health
                     address:
                        name:Division of Hematology/Oncology, Perlmutter Cancer Center, NYU Langone Health, New York, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sai-Ching Jim Yeung
               affiliation:
                     name:The University of Texas MD Anderson Cancer Center
                     address:
                        name:Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
                     name:The University of Texas MD Anderson Cancer Center
                     address:
                        name:Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis
      description:Metaplastic breast cancer (MpBC) is a rare histological subtype of breast cancer recognized as a unique pathologic entity in 2000. However, the pathogenesis, optimal therapy, and prognosis of MpBC and the potential effect of systemic treatments on different subtypes of MpBC are not well defined. A retrospective population-based study was performed to identify breast cancer patients with MpBC and other triple-negative breast cancers (TNBC) between 2010 and 2014 using the surveillance, Epidemiology, and End Results (SEER) database. Chi-square test was used to analyze characteristics between subgroups. Kaplan–Meier analysis and Multivariate Cox regressions were used to evaluate overall survival (OS) of MpBC, TNBC, and MpBC subgroups. Competing risk analysis and multivariate regression model of competing risk were used to assess breast cancer-specific survival (BCSS) of MpBC and TNBC We identified a study cohort of 22,433 patients (1112 MpBC and 21,321 TNBC). MpBC correlated with older population, larger tumor size and less lymph node involvement, and TNBC phenotype. Patients with MpBC especially with triple-negative subtype (TN-MpBC) had worse survival than the overall TNBC population. However, the prognosis of MpBC without triple-negative subtype (non-TN MpBC) was not different from that of TNBC. In Kaplan–Meier analysis, chemotherapy was not associated with significant difference in OS of TN-MpBC. In non-TN MpBC group, the 3-year OS was 79.8% for patients receiving chemotherapy and 70.5% in patients without chemotherapy, and chemotherapy was associated (P = 0.033) with improved OS. Within the MpBC patients, radiotherapy was significantly (HR 1.544; 95% CI 1.148–2.078; P = 0.004) associated with improved OS and (HR 1.474; 95% CI 1.067–2.040; P = 0.019) BCSS. Patients with TN-MpBC had worse prognosis than TNBC and chemotherapy was not associated with improved survival. In contrast, non-TN MpBC may derive survival benefit from chemotherapy and radiotherapy.
      datePublished:2018-10-19T00:00:00Z
      dateModified:2018-10-19T00:00:00Z
      pageStart:329
      pageEnd:341
      sameAs:https://doi.org/10.1007/s10549-018-5005-6
      keywords:
         Metaplastic breast cancer
         Breast cancer subtype
         Chemotherapy
         Radiotherapy
         Prognosis
         Cancer-specific survival
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-5005-6/MediaObjects/10549_2018_5005_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-5005-6/MediaObjects/10549_2018_5005_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-5005-6/MediaObjects/10549_2018_5005_Fig3_HTML.png
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:173
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Xuexin He
            url:http://orcid.org/0000-0002-4178-1339
            affiliation:
                  name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
                  address:
                     name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
                     type:PostalAddress
                  type:Organization
                  name:The University of Texas MD Anderson Cancer Center
                  address:
                     name:Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Jiali Ji
            affiliation:
                  name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
                  address:
                     name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rongrong Dong
            affiliation:
                  name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
                  address:
                     name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hong Liu
            affiliation:
                  name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
                  address:
                     name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xiaolan Dai
            affiliation:
                  name:Shantou University
                  address:
                     name:Department of Pharmacology, Shantou University, Shantou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chongjian Wang
            affiliation:
                  name:Zhengzhou University
                  address:
                     name:Department of Biostatistics, Zhengzhou University, Zhengzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Francisco J. Esteva
            affiliation:
                  name:NYU Langone Health
                  address:
                     name:Division of Hematology/Oncology, Perlmutter Cancer Center, NYU Langone Health, New York, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sai-Ching Jim Yeung
            affiliation:
                  name:The University of Texas MD Anderson Cancer Center
                  address:
                     name:Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
                  name:The University of Texas MD Anderson Cancer Center
                  address:
                     name:Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:173
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
      address:
         name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
         type:PostalAddress
      name:The University of Texas MD Anderson Cancer Center
      address:
         name:Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
      address:
         name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
         type:PostalAddress
      name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
      address:
         name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
         type:PostalAddress
      name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
      address:
         name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
         type:PostalAddress
      name:Shantou University
      address:
         name:Department of Pharmacology, Shantou University, Shantou, China
         type:PostalAddress
      name:Zhengzhou University
      address:
         name:Department of Biostatistics, Zhengzhou University, Zhengzhou, China
         type:PostalAddress
      name:NYU Langone Health
      address:
         name:Division of Hematology/Oncology, Perlmutter Cancer Center, NYU Langone Health, New York, USA
         type:PostalAddress
      name:The University of Texas MD Anderson Cancer Center
      address:
         name:Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:The University of Texas MD Anderson Cancer Center
      address:
         name:Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Xuexin He
      url:http://orcid.org/0000-0002-4178-1339
      affiliation:
            name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
            address:
               name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
               type:PostalAddress
            type:Organization
            name:The University of Texas MD Anderson Cancer Center
            address:
               name:Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Jiali Ji
      affiliation:
            name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
            address:
               name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
               type:PostalAddress
            type:Organization
      name:Rongrong Dong
      affiliation:
            name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
            address:
               name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
               type:PostalAddress
            type:Organization
      name:Hong Liu
      affiliation:
            name:The 2nd Affiliated Hospital, School of Medicine, Zhejiang University
            address:
               name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
               type:PostalAddress
            type:Organization
      name:Xiaolan Dai
      affiliation:
            name:Shantou University
            address:
               name:Department of Pharmacology, Shantou University, Shantou, China
               type:PostalAddress
            type:Organization
      name:Chongjian Wang
      affiliation:
            name:Zhengzhou University
            address:
               name:Department of Biostatistics, Zhengzhou University, Zhengzhou, China
               type:PostalAddress
            type:Organization
      name:Francisco J. Esteva
      affiliation:
            name:NYU Langone Health
            address:
               name:Division of Hematology/Oncology, Perlmutter Cancer Center, NYU Langone Health, New York, USA
               type:PostalAddress
            type:Organization
      name:Sai-Ching Jim Yeung
      affiliation:
            name:The University of Texas MD Anderson Cancer Center
            address:
               name:Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
            name:The University of Texas MD Anderson Cancer Center
            address:
               name:Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
      name:Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, USA
      name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
      name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
      name:Department of Medical Oncology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
      name:Department of Pharmacology, Shantou University, Shantou, China
      name:Department of Biostatistics, Zhengzhou University, Zhengzhou, China
      name:Division of Hematology/Oncology, Perlmutter Cancer Center, NYU Langone Health, New York, USA
      name:Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, USA
      name:Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(159)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Foundation
  • Prism.js

CDN Services {📦}

  • Crossref

4.07s.